Remdesivir triphosphate inhibits the RNA-dependent RNA polymerase also from flaviviruses
Remdesivir is known to inhibit RNA-dependent RNA-polymerases (RdRps) from different viral families, such as Filoviridae (Ebola) and Coronaviridae (SARS-CoV, SARS-CoV-2, MERS). Researchers from IOCB Prague, led by Radim Nencka and Evžen Bouřa, tested its ability to inhibit RdRps also from the Flaviviridae family.
To be able to test directly in vitro on recombinant flaviviral polymerases, the researchers didn't use remdesivir itself, but the active species produced from remdesivir in cells.
Their results, published now in the Antiviral Research journal, show that remdesivir can efficiently inhibit RdRps from viruses causing such severe illnesses as Yellow fever, West Nile fever, Japanese and Tick-borne encephalitis, Zika, and Dengue.
The study demonstrates that remdesivir or its derivatives have the potential to become a broad-spectrum antiviral agent effective against many RNA viruses.
Read the paper:
- Konkolova, E.; Dejmek, M.; Hřebabecký, H.; Šála, M.; Böserle, J.; Nencka, R.; Boura, E. Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses. Antiviral Research 2020, 182, 104899. https://doi.org/10.1016/j.antiviral.2020.104899
